

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



Kidney Cancer

Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Needed?

Giacomo Novara^a, Vincenzo Ficarra^{a,*}, Alessandro Antonelli^b, Walter Artibani^a, Roberto Bertini^c, Marco Carini^d, Sergio Cosciani Cunico^b, Ciro Imbimbo^e, Nicola Longo^e, Guido Martignoni^f, Giuseppe Martorana^g, Andrea Minervini^d, Vincenzo Mirone^e, Francesco Montorsi^c, Roberto Schiavina^g, Claudio Simeone^b, Sergio Serni^d, Alchiede Simonato^h, Salvatore Siracusanoⁱ, Alessandro Volpe^j, Giorgio Carmignani^h
members of the SATURN Project–LUNA Foundation¹

^a University of Padua, Padua, Italy

^b University of Brescia, Brescia, Italy

^c Vita-Salute University San Raffaele, Milan, Italy

^d University of Florence, Florence, Italy

^e University Federico II, Naples, Italy

^f University of Verona, Verona, Italy

^g University of Bologna, Bologna, Italy

^h University of Genova, Genova, Italy

ⁱ University of Trieste, Trieste, Italy

^j University of Eastern Piedmont, Novara, Italy

Article info

Article history:

Accepted July 9, 2010

Published online ahead of
print on July 23, 2010

Keywords:

Kidney neoplasm
Renal cell carcinoma
TNM
Nephrectomy

Abstract

Background: A new edition of the TNM was recently released that includes modifications for the staging system of kidney cancers. Specifically, T2 cancers were subclassified into T2a and T2b (≤ 10 cm vs > 10 cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a cancers, and those with adrenal involvement were classified as T4 cancers.

Objective: Our aim was to validate the recently released edition of the TNM staging system for primary tumor classification in kidney cancer.

Design, setting, and participants: Our multicenter retrospective study consisted of 5339 patients treated in 16 academic Italian centers.

Intervention: Patients underwent either radical or partial nephrectomy.

Measurements: Univariable and multivariable Cox regression models addressed cancer-specific survival (CSS) after surgery.

Results and limitations: In the study, 1897 patients (35.5%) were classified as pT1a, 1453 (27%) as pT1b, 437 (8%) as pT2a, 153 (3%) as pT2b, 1059 (20%) as pT3a, 117

¹ See appendix.

* Corresponding author. Department of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Monoblocco Ospedaliero, IV floor, Via Giustiniani 2, 35100 - Padua, Italy.
Tel. +39 0498212720; Fax: +39 0498218757.

E-mail address: vincenzo.ficarra@unipd.it (V. Ficarra).

(2%) as pT3b, 26 (0.5%) as pT3c, and 197 (4%) as pT4. At a median follow-up of 42 mo, 786 (15%) had died of disease. In univariable analysis, patients with pT2b and pT3a tumors had similar CSS, as did patients with pT3c and pT4 tumors. Moreover, both pT3a and pT3b stages included patients with heterogeneous outcomes. In multivariable analysis, the novel classification of the primary tumor was a powerful independent predictor of CSS (p for trend <0.0001). However, the substratification of pT1 tumors did not retain an independent predictive role. The major limitations of the study are retrospective design, lack of central pathologic review, and the small number of patients included in some substages.

Conclusions: The recently released seventh edition of the primary tumor staging system for kidney tumors is a powerful predictor of CSS. However, some of the substages identified by the classification have overlapping prognoses, and other substages include patients with heterogeneous outcomes. The few modifications included in this edition may have not resolved the most critical issues in the previous version.

© 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.

1. Introduction

TNM classification is the globally accepted method of describing the anatomic extent of cancer. In kidney tumors, the outcome stratification proposed in the sixth edition of the TNM, published in 2002, was validated in several studies [1–3]. However, some studies suggested that patients with localized cancers could be better dichotomized around a tumor diameter of 5–6 cm [4–7] and that T3a and pT3b stages were heterogeneous [8]. Consequently, several proposals for further updates were implemented, both for localized [9,10] and locally advanced [11–17] disease.

Very recently, the Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) released the seventh edition of the staging system, which took effect on January 1, 2010. In this latest update, some modifications were made to the staging system for kidney tumors. In comparison with the sixth edition of TNM, T2 cancers were subclassified into two subgroups based on a tumor size cut-off point of 10 cm ($T2a \leq 10$ cm vs $T2b > 10$ cm). Moreover, tumors with renal vein involvement or perinephric fat involvement were classified as T3a, whereas those with adrenal involvement were classified as T4 cancers. All the other categories were unchanged [18].

The purpose of the present study was to validate the recently released seventh edition of the TNM staging system for primary tumor classification in kidney tumors in a multicenter series of patients with renal cell carcinoma (RCC) treated with radical nephrectomy (RN) or partial nephrectomy (PN) in 16 academic centers in Italy.

2. Patients and methods

The Surveillance and Treatment Update Renal Neoplasms (SATURN) project was promoted by LUNA, the Leading Urological No-Profit Foundation for Advanced Research of the Società Italiana di Urologia (ie, the Italian Society of Urology). A total of 16 academic centers in Italy provided data. The database comprised 5893 patients who underwent RN or PN between 1995 and 2007 because of a suspicion of kidney cancer. The patients with benign histology ($n = 430$), those lacking histologic subtypes of the tumor ($n = 85$), and those where the

concomitant presence of some adverse pathologic features was not reported ($n = 39$) were excluded from the study. The 5339 remaining patients were the subjects of the present analysis.

The mode of presentation was distinguished according to the Patard classification [19]. Clinical staging included at least abdominal computed tomography (CT) scans and chest x-rays. Bone scans and brain CT scans were obtained only when indicated by signs and symptoms.

Surgery was performed by several surgeons according to the standard criteria for RN (ie, extrafascial dissection of the kidney). The hilar and regional lymph nodes adjacent to the ipsilateral great vessel generally were resected, along with enlarged lymph nodes if they were abnormal on preoperative CT scans or palpable intraoperatively. Extended lymphadenectomy was routinely performed in a few centers. In patients with a contralateral normal kidney, elective PN had been routinely indicated in the presence of single peripheral tumors ≤ 4 cm, although some referral centers also performed elective PN in the case of larger tumors.

2.1. Pathologic evaluation

All surgical specimens were processed according to standard pathologic procedures at each institution. Tumor stage was reassigned according to the recently released seventh edition of the AJCC-UICC TNM classification. Specifically, T2 cancers were subclassified into two subgroups based on a tumor size cut-off point of 10 cm ($T2a \leq 10$ cm vs $T2b > 10$ cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a, whereas those with adrenal involvement were classified as T4 cancers. Classification of T1 tumors, as well as of those with vena cava thrombus and Gerota fascia invasion, was unchanged [18].

The Heidelberg and Fuhrman classifications were used to assign histologic type and nuclear grade, respectively [20,21]. No central pathologic slide review was performed.

2.2. Follow-up regimen

Patients were generally observed every 3–4 mo for the first year after surgery, every 6 mo from the second through the fifth years, and annually thereafter. Follow-up consisted of a history, a physical examination, routine blood work and serum chemistry studies, chest radiography, and radiographic evaluation of the contralateral or remnant kidney. Elective bone scan, chest CT, and magnetic resonance imaging were performed when clinically indicated.

Cause of death was determined by the treating physicians, by chart review corroborated by death certificates, or by death certificates alone.

2.3. Statistical analysis

Continuous variables were reported as median value and interquartile ranges (IQRs). The Kaplan-Meier method was used to calculate survival functions, and differences were assessed with the log-rank statistic. Univariable and multivariable Cox regression models addressed time to cancer-specific mortality after surgery. Patients alive and disease free were censored. Statistical significance in this study was set as $p < 0.05$. All reported p values are two sided. Analyses were performed with SPSS v.16.0 (SPSS Inc, Chicago, IL, USA) by one of the authors (GN).

3. Results

Table 1 summarizes the clinical and pathologic features of the 5339 analyzed patients. Based on the novel TNM staging system, 1897 of the patients (35.5%) were classified as pT1a, 1453 (27%) as pT1b, 437 (8%) as pT2a, 153 (3%) as pT2b, 1059 (20%) as pT3a, 117 (2%) as pT3b, 26 (0.5%) as pT3c, and 197 (4%) as pT4.

At a median follow-up of 42 mo (IQR: 24–75 mo), 3949 patients (74%) were alive and disease free, 786 (15%) had died of disease, and 335 (6%) had died of other causes. Median follow-up of the 3987 living patients was 48 mo (IQR: 25–84 mo). The overall 5- and 10-yr cancer-specific survival (CSS) estimates were 83.2% (standard error [SE]: 0.6%) and 76.6% (SE: 0.9%), respectively.

According to the 2009 TNM staging system, 5-yr CSS was 94.9% (SE: 0.6%) in pT1a, 92.6% (SE: 0.8%) in pT1b, 85.4% (SE: 1.9%) in pT2a, 70% (SE: 4.1%) in pT2b, 64.7% (SE: 1.8%) in pT3a, 54.7% (SE: 5.9%) in pT3b, 17.9% (SE: 10.1%) in pT3c, and 27.1% (SE: 4.0%) in pT4 (pooled over strata $p < 0.00001$) (Fig. 1). All the pairwise survival differences among the different pT stages were statistically significant with the exception of those observed between pT2b and pT3a cancers (log-rank pairwise $p = 0.34$) and between pT3c and pT4 cancers (pairwise $p = 0.26$). Considering only the 4848 cases with N0/NxM0 disease, the survival differences between pT1a and pT1b, pT2b and pT3a, pT3a and pT3b, and pT3c and pT4 were not statistically significant (pairwise p values > 0.05 ; data not extensively shown).

The pT3a subcategory was composed of 503 cases (47%) with perinephric fat invasion only, 401 (38%) with renal vein invasion only, and 155 (15%) with concomitant perinephric fat and renal vein invasion. Patients with isolated perinephric fat and renal vein invasion had similar outcomes (pairwise $p = 0.05$), but the patients with the two concomitant features had significantly lower CSS (pairwise p values < 0.0001) (Fig. 2). Considering only the 866 cases with pT3aN0M0 RCC, patients with renal vein invasion had the highest CSS, followed by those with only perirenal fat invasion and by those with the two concomitant features, with all the survival differences being statistically significant (pairwise p values < 0.045 ; data not extensively shown).

The pT3b subcategory included 69 cases (59%) with infradiaphragmatic vena caval thrombus only, and 48 cases (41%) with concomitant infradiaphragmatic vena caval thrombus and perirenal fat invasion. Those patients with the two concomitant features had significantly lower CSS

Table 1 – Clinical and pathologic features of the 5339 analyzed patients

Variables	
Age, yr, median (IQR)	63 (54–71)
Gender, No. (%)	
Male	3538 (66)
Female	1801 (34)
Mode of presentation, No. (%) [*]	
Incidental	3335 (62)
Local symptoms	1438 (27)
Systemic symptoms	260 (5)
Type of surgery, No. (%)	
Radical nephrectomy	3799 (71)
Elective partial nephrectomy	1311 (25)
Imperative partial nephrectomy	229 (4)
Histologic subtype, No. (%)	
Clear cell	4334 (81)
Papillary	577 (11)
Chromophobe	291 (6)
Collecting duct	47 (1)
Unclassified	90 (2)
Pathologic tumor size, median (IQR)	5 (3.5–7)
Pathologic T stage (TNM 2002), No. (%)	
T1a	1897 (35.5)
T1b	1453 (27)
T2	590 (11)
T3a	547 (10)
T3b	710 (13)
T3c	26 (0.5)
T4	116 (2)
Pathologic T stage, TNM 2009, No. (%)	
T1a	1897 (35.5)
T1b	1453 (27)
T2a	437 (8)
T2b	153 (3)
T3a	1059 (20)
T3b	117 (2)
T3c	26 (0.5)
T4	197 (4)
Pathologic N stage, No. (%)	
Nx	3062 (57)
N0	2034 (38)
N1	116 (2)
N2	127 (2)
M stage, No. (%)	
M0	5016 (94)
M1	323 (6)
Fuhrman nuclear grade, No. (%) ^{**}	
G1	621 (11)
G2	2783 (50)
G3	1399 (25)
G4	408 (7)

IQR = interquartile range.

^{*} Missing in 306 cases (6%).

^{**} Missing in 395 cases (7%).

compared with those with thrombus only ($p = 0.0007$) (Fig. 3). Similar statistics were obtained limiting the analysis to the 84 pT3bN0M0 cases ($p = 0.005$).

The pT3c subcategory was composed of 16 patients (61%) with supradiaphragmatic vena caval thrombus only, and 10 patients (39%) with concomitant supradiaphragmatic vena caval thrombus and perirenal fat invasion. The two subgroups of pT3c patients had overlapping CSS




Fig. 1 – Cancer-specific survival (CSS) probability according to the 2009 TNM staging system (log rank pooled over strata $p < 0.0001$). Five-year CSS was 94.9% in pT1a (blue curve), 92.6% in pT1b (green curve), 85.4% in pT2a (gray curve), 70% in pT2b (violet curve), 64.7% in pT3a (yellow curve), 54.7 in pT3b (red curve), 17.9 in pT3c (light blue curve), and 27.1% in pT4 (light gray curve). All the pairwise survival differences among the different pT stages were statistically significant with the exception of those observed between pT2b and pT3a cancers (log-rank pairwise $p = 0.34$) and between pT3c and pT4 cancers (log-rank pairwise $p = 0.26$).




Fig. 2 – Cancer-specific survival (CSS) probability within the pT3a subcategory (log-rank pooled over strata $p < 0.0001$). Five-year CSS was 75% in patients with renal vein invasion only (blue curve), 66.9% in patients with perirenal fat invasion only (green curve), and 32.4% in patients with the two concomitant features (red curve). Renal vein invasion only versus perirenal fat invasion only: log-rank pairwise $p = 0.05$. Concomitant renal vein and perirenal fat invasion versus each individual features: log-rank pairwise $p < 0.0001$.




Fig. 3 – Cancer-specific survival (CSS) probability within the pT3b subcategory. Five-year CSS was 65.9% in patients with infradiaphragmatic vena caval thrombus only (blue curve) and 36.5% in patients with concomitant invasion of the perirenal fat (green curve). Log-rank pooled over strata $p = 0.0007$.

($p = 0.33$) (Fig. 4). Similar figures were obtained limiting the analysis to the 12 pT3cN0M0 cases ($p = 0.135$).

Evaluating the prognostic role of the proximal extension of tumor thrombus with renal or caval veins, all the CSS differences among the 628 patients with renal vein, 146 with infradiaphragmatic, and 27 with supradiaphragmatic vena caval thrombus were statistically significant (p values < 0.009). However, considering only the 405 patients with N0M0 disease and isolated tumor thrombus in the absence of other adverse pathologic features, the CSS of those with renal vein thrombosis and infradiaphragmatic vena caval thrombus was similar ($p = 0.267$). Patients with infradiaphragmatic or supradiaphragmatic vena caval thrombus had a similar prognosis ($p = 0.067$).

The pT4 subcategory included 68 cases (29%) with tumor extending beyond the Gerota fascia, 81 cases (41%) with adrenal gland invasion, and 48 cases (24%) with the two concomitant features. The three subgroups of pT4 patients had similar outcomes ($p = 0.32$) (Fig. 5). Similar figures were obtained limiting the analysis to the 97 pT4N0M0 cases (p values > 0.05 ; data not extensively shown). Table 2 summarizes the data of univariable and multivariable analyses for CSS.

On multivariable Cox regression analyses, the T stage according to the 2009 staging system was an independent predictor of CSS (p for trend < 0.0001), once adjusted for the effect of all the other covariates. Notably, the substratification of T1 tumors was not an independent predictor of survival in multivariable analysis (hazard ratio [HR]: 1.1; $p = 0.70$). Limiting the analysis to N0M0 cases, the 2009 T stage retained an independent predictor role (p for trend




Fig. 4 – Cancer-specific survival (CSS) probability within the pT3c subcategory. Three-year CSS was 30% in patients with supradiaphragmatic vena caval thrombus only (blue curve) and 20% in patients with concomitant invasion of the perirenal fat (green curve). Log-rank pooled over strata $p = 0.33$.

<0.0001). However, pT1b (HR: 0.9; $p = 0.463$) and pT2a (HR: 1.5; $p = 0.77$) were not statistically significantly different from the reference pT1a group (data not extensively shown).

4. Discussion

We have reported what is to our knowledge the first attempt to validate the recently released seventh edition of the TNM staging system for RCC. In the present series, the novel classification of the primary tumor was a powerful independent predictor of CSS. However, some of the substages identified by the classification had overlapping prognoses (pT2b and pT3a; pT3c and pT4 RCC), whereas both pT3a and pT3b stages included patients with heterogeneous outcomes. Lastly, in multivariable analysis, the substratification of pT1 RCC into pT1a and pT1b did not retain an independent predictive role for CSS.

The TNM staging system should effectively communicate critical tumor characteristics, aid the clinician in the appropriate selection of therapeutic options, stratify the patient's risk of cancer progression or cancer death, allow the evaluation of treatment results, make data comparison from different centers easy, and determine the selection criteria for clinical trials [22]. To accomplish all these purposes, in 2002, the UICC introduced a structured process for regular updates of the TNM classification system [22]. Applying such a process, the seventh edition of the staging system for RCC introduced a subclassification of T2 into two subgroups based on a tumor size cut-off point of 10 cm (T2a ≤ 10 cm vs T2b >10 cm) and reclassified direct adrenal involvement as T4 cancers [18].




Fig. 5 – Cancer-specific survival (CSS) probability within the pT4 subcategory (log-rank pooled over strata $p = 0.32$). Five-year CSS was 30.9% in patients with adrenal gland invasion only (blue curve), 20% in patients with invasion of the Gerota fascia (green curve), and 34.8% in patients with the two concomitant features (red curve). Gerota fascia invasion only versus adrenal gland invasion only: log-rank pairwise $p = 0.14$. Concomitant Gerota fascia and adrenal gland invasion versus adrenal gland invasion only: log-rank pairwise $p = 0.47$. Concomitant Gerota fascia and adrenal gland invasion versus Gerota fascia invasion only: log rank pairwise $p = 0.53$.

Regarding localized RCC, the T2 subclassification was based on a study from the Mayo Clinic in which the 10-cm break point was able to stratify T2 patients into two substages with statistically different survival probabilities, both better than those observed in pT3a cases [10]. In the present analysis, the CSS probabilities of pT2b patients were similar to those of the new pT3a substage. That result might be due to the small number of patients included in these subgroups (only 3%), as well as the overall improvement of the outcomes of the pT3a patients after removal of cases with direct adrenal involvement, reclassified as pT4 in the new TNM. On the whole, the modification of RCC primary tumor classification wound up splitting localized cancers into four subgroups (T1a vs T1b vs T2a vs T2b) that were numerically imbalanced, with most of the patients still classified as T1. Moreover, in terms of clinical staging, the subclassification of T1 cancers is losing its main clinical relevance because the indication for elective PN in tumors has been extended to tumors >4 cm [23,24]. Consequently, a staging system based on a cut-off point in the range of 5–6 cm might be more suitable from a clinical point of view to indicate those patients suitable for PN as well as, according to the available data, to dichotomize the cancer-related outcome of localized cancers [4–7,9].

With regard to the updates in the staging of locally advanced RCC, the choice to move direct adrenal invasion into the pT4 stage was driven by several studies, all of which demonstrated that tumors with adrenal invasion had the

Table 2 – Univariable and multivariable Cox regression analyses of TNM staging system for prediction of cancer-specific mortality in 5339 patients (786 cancer-specific deaths)

Parameter	Univariable analysis			Multivariable analysis		
	HR	95% CI	p value	HR	95% CI	p value
Age, continuous	1.02	1.01–1.02	<0.001	1.01	1–1.02	0.002
Gender			0.016			<0.001
Male	1	Reference	–	1	Reference	–
Female	0.8	0.7–0.9	–	0.7	0.6–0.9	–
Mode of presentation			<0.001			<0.001
Incidental	1	Reference	–	1	Reference	–
Local symptoms	2.6	2.3–3.1	<0.001	1.4	1.2–1.7	<0.001
Systemic symptoms	6.9	5.6–8.6	<0.001	2.0	1.5–2.5	<0.001
Type of surgery			<0.001			0.050
Radical nephrectomy	1	Reference	–	1	Reference	–
Elective partial nephrectomy	0.2	0.1–0.3	<0.001	0.6	0.5–0.9	0.019
Imperative partial nephrectomy	0.6	0.4–0.9	0.009	1.1	0.7–1.7	0.655
Histologic subtype			<0.001			<0.001
Clear cell	1	Reference	–	1	Reference	–
Papillary	0.8	0.6–0.9	0.032	0.7	0.5–0.9	0.024
Chromophobe	0.4	0.3–0.7	<0.001	0.6	0.4–0.9	0.040
Collecting duct	4.1	2.6–6.5	<0.001	2.4	1.4–4.0	0.001
Unclassified	2.9	2.0–4.2	<0.001	1.7	1.2–2.5	0.009
Pathologic tumor size, continuous	1.2	1.1–1.2	<0.001	1.03	1.0–1.06	0.016
Pathologic T stage			<0.001			<0.001
T1a	1	Reference	–	1	Reference	–
T1b	1.6	1.2–2.2	0.001	1.1	0.8–1.5	0.700
T2a	3.6	2.6–4.9	<0.001	1.8	1.2–2.6	0.002
T2b	7.2	5–10.3	<0.001	2.6	1.6–4.2	<0.001
T3a	8.4	6.6–10.8	<0.001	2.8	2.1–3.9	<0.001
T3b	14.2	9.9–20.6	<0.001	3.8	2.5–5.9	<0.001
T3c	36.7	21.5–63.2	<0.001	6.4	3.3–12.7	<0.001
T4	26.6	20.0–35.2	<0.001	3.1	2.1–4.7	<0.001
Pathologic N stage			<0.001			<0.001
N0	1	Reference	–	1	Reference	–
Nx	0.6	0.5–0.7	<0.001	0.9	0.7–1.1	0.293
N1	6.9	5.3–8.9	<0.001	2.2	1.6–2.9	<0.001
N2	8.7	6.9–10.9	<0.001	2.2	1.7–2.9	<0.001
M stage			<0.001			<0.001
M0	1	Reference	–	1	Reference	–
M+	12.7	10.9–14.8	–	4.1	3.4–4.9	–
Fuhrman nuclear grade			<0.001			<0.001
G1	1	Reference	–	1	Reference	–
G2	2.0	1.4–3.0	<0.001	1.6	1.01–2.4	0.047
G3	6.4	4.3–9.5	<0.001	2.7	1.7–4.1	<0.001
G4	18.0	12–26.9	<0.001	3.4	2.1–5.4	<0.001

CI = confidence interval; HR = hazard ratio.

same aggressive clinical behavior of those extending beyond the Gerota fascia [12–14,16,17]. However, the pT3a and pT3b stages both included patients with different CSS (ie, those presenting concomitant unfavorable features). The opportunity to stratify the outcome of patients with locally advanced RCC taking in account the concomitant presence of multiple concomitant pathologic features had been proposed in three previous studies, all of which aimed at improving the primary tumor classification of locally advanced RCC [12–14]. Specifically, Thompson et al had reported on about 700 patients treated at the Mayo Clinic, proposing to distinguish locally advanced RCC into five subgroups (pT3a, renal vein thrombosis only; pT3b, fat

invasion only; pT3c, renal vein thrombosis and perirenal fat infiltration or subdiaphragmatic vena cava thrombosis only; pT3d, subdiaphragmatic vena cava thrombosis with perirenal fat infiltration or supradiaphragmatic inferior vena cava thrombosis; and pT4, extension beyond the Gerota fascia or ipsilateral adrenal invasion) [12]. However, although all components of the proposed reclassification were statistically significantly different from the reference group consisting of patients with renal vein thrombosis only after adjusting for N and M stages, the survival probabilities of all the subgroups were clearly overlapping in Thompson's paper. Similarly, Ficarra et al evaluated 227 patients treated at two academic Italian centers, proposing

to distinguish pT3a (perirenal fat invasion or renal vein thrombosis or thrombosis within the vena cava below the diaphragm), pT3b (renal vein thrombosis or thrombosis within the vena cava below the diaphragm associated with perirenal fat invasion), and pT4 (adrenal gland invasion or Gerota fascia invasion or thrombosis within the vena cava above the diaphragm) [13]. That proposal was further updated in a larger analysis involving about 2000 patients with pT3–pT4 RCC treated at 12 European centers. The data from that analysis suggested the possibility of stratifying locally advanced RCC as follows: pT3a, renal vein or infradiaphragmatic vena caval thrombosis, or perirenal fat invasion; pT3b, ipsilateral adrenal direct invasion or venous thrombosis plus perirenal fat invasion; pT4, venous thrombosis and ipsilateral adrenal direct invasion, supra-diaphragmatic vena caval thrombosis or tumors extending beyond Gerota fascia [14]. However, none of these proposals for reclassification of locally advanced RCC were included in the new staging system, and the prognostic role of the concomitant presence of adverse pathologic features (eg, perirenal fat involvement and extent of tumor thrombosis) was not taken in account.

There are several limitations to our study. First and foremost are those inherent to any retrospective analysis. In addition, the population in this study underwent surgery in multiple centers, and specimens were evaluated by multiple pathologists without slide review. However, all surgeons operated at selected centers with significant experience in RCC management, which might increase the external validity of the data as compared with the single-center, single-surgeon setting. Similarly, although it may be preferable for a single pathologist specialized in genitourinary pathology to review each specimen, the present study reflects a real-world scenario. Moreover, although the series was very large, the number of pT2b, pT3b, pT3c, and pT4 cases was quite low, which might have resulted in some underpowered statistical analyses. This low number partially reflects the stage's distribution of RCC at surgery but is significantly affected by the excessive tendency to sub-stratify in the current TNM staging system, which includes four substages for localized RCC and four for locally advanced RCC. Finally, most of the patients who had a recurrence of disease in the present cohort did not have access to targeted therapies and were treated before the development of tyrosine kinase and mammalian target of rapamycin inhibitors.

5. Conclusions

In the present series, the recently released seventh edition of the primary tumor staging system for RCC was a powerful independent predictor of CSS. However, some of the substages identified by the classification had overlapping prognoses, whereas other substages included patients with heterogeneous outcomes. Although in the past few years several reports have highlighted the need to change the TNM classification both for localized and locally advanced stages, only a few modifications have been included in the latest version of the TNM.

Author contributions: Vincenzo Ficarra had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Ficarra, Longo, Simonato.

Acquisition of data: Novara, Ficarra, Antonelli, Artibani, Bertini, Carini, Cosciani Cunico, Imbimbo, Longo, Martignoni, Martorana, Minervini, Mirone, Montorsi, Schiavina, Simeone, Serni, Simonato, Siracusano, Volpe, Carmignani.

Analysis and interpretation of data: Novara, Ficarra.

Drafting of the manuscript: Novara, Ficarra.

Critical revision of the manuscript for important intellectual content: Novara, Ficarra, Antonelli, Artibani, Bertini, Carini, Cosciani Cunico, Imbimbo, Longo, Martignoni, Martorana, Minervini, Mirone, Montorsi, Schiavina, Simeone, Serni, Simonato, Siracusano, Volpe, Carmignani.

Statistical analysis: Novara.

Obtaining funding: None.

Administrative, technical, or material support: None.

Supervision: None.

Other (specify): None.

Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

Funding/Support and role of the sponsor: The LUNA Foundation received unrestricted grants from Bayer and Pfizer, which made the SATURN project possible. Sponsors had no role in study design, data collection, management, interpretation, analysis, or in manuscript preparation, review, and approval.

Appendix A. Members of the SATURN Project

European Institute of Oncology, Milan: O. De Cobelli
 University of Bologna: G. Martorana, R. Schiavina
 University of Brescia: A. Antonelli, S. Corti, S. Cosciani Cunico, C. Simeone
 University of Catania: M. Castelli, S. Cimino, V. Favilla, G. Morgia
 University of Eastern Piedmont, Novara: M. Billia, C. Terrone, A. Volpe
 University Federico II, Naples: C. Imbimbo, N. Longo, V. Mirone
 University of Florence: M. Carini, L. Masieri, A. Minervini, S. Serni
 University of Genova: G. Carmignani, F. Oneto, A. Simonato, V. Varca
 University of Milan: F. Rocco
 University of Padua: W. Artibani, V. Ficarra, G. Novara
 University of Perugia: E. Costantini, M. Porena, A. Zucchi
 University of Sassari/Messina: G. Morgia
 University of Trieste: S. Ciciliato, N. Lampropoulou, S. Siracusano
 University of Turin, Molinette Hospital: D. Fontana, P. Gontero, A. Tizzani
 University of Verona (Pathology): M. Brunelli, G. Martignoni
 University of Verona (Urology): C. Valotto, F. Zattoni

Vita-Salute University San Raffaele, Milan: R. Bertini, F. Montorsi, G. Petralia, M. Roscigno, E. Strada

References

- [1] Ficarra V, Schips L, Guillè F, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. *Cancer* 2005;104:968–74.
- [2] Frank I, Blute ML, Leibovich BC, et al. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. *J Urol* 2005;173:1889–92.
- [3] Bedke J, Pritsch M, Buse S, et al. Prognostic stratification of localized renal cell carcinoma by tumor size. *J Urol* 2008;180:62–7.
- [4] Kinouchi T, Saiki S, Meguro N, et al. Impact of tumor size on the clinical outcomes of patients with Robson stage I renal cell carcinoma. *Cancer* 1999;689–95.
- [5] Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. *Urology* 2002;59:532–7.
- [6] Elmore JM, Kadesky KT, Koeneman KS, Sagalowsky AI. Reassessment of the 1997 TNM classification system for renal cell carcinoma. *Cancer* 2003;98:2329–34.
- [7] Igarashi T, Tobe T, Nakatsu HO, et al. The impact of a 4 cm. cutoff point for stratification of T1N0M0 renal cell carcinoma after radical nephrectomy. *J Urol* 2001;165:1103–6.
- [8] Ficarra V, Galfano A, Mancini M, et al. TNM staging system for renal-cell carcinoma: current status and future perspectives. *Lancet Oncol* 2007;8:554–8.
- [9] Ficarra V, Guillè F, Schips L, et al. Proposal for revision of the TNM classification system for renal cell carcinoma. *Cancer* 2005;104:2116–23.
- [10] Frank I, Blute ML, Leibovich BC, et al. pT2 classification for renal cell carcinoma. Can its accuracy be improved? *J Urol* 2005;173:380–4.
- [11] Leibovich BC, Cheville JC, Lohse CM, et al. Cancer specific survival for patients with pT3 renal cell carcinoma—an the 2002 primary tumor classification be improved? *J Urol* 2005;173:716–9.
- [12] Thompson RH, Cheville JC, Lohse CM, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. *Cancer* 2005;104:53–60.
- [13] Ficarra V, Novara G, Iafrate M, et al. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3–4) renal cell carcinoma according to the cancer-related outcome. *Eur Urol* 2007;51:722–31.
- [14] Ficarra V, Galfano A, Guillè F, et al. A new staging system for locally advanced (pT3–4) renal cell carcinoma: a multicenter European study including 2,000 patients. *J Urol* 2007;178:418–24.
- [15] Margulis V, Tamboli P, Matin SF, et al. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. *Cancer* 2007;109:2439–44.
- [16] Jung SJ, Ro JY, Truong LD, Ayala AG, Shen SS. Reappraisal of T3N0/NxM0 renal cell carcinoma: significance of extent of fat invasion, renal vein invasion, and adrenal invasion. *Hum Pathol* 2008;39:1689–94.
- [17] Fujita T, Iwamura M, Yanagisawa N, Muramoto M, Okayasu I, Baba S. Reclassification of the current tumor, node, metastasis staging in pT3 renal cell carcinoma. *Int J Urol* 2008;15:582–6.
- [18] Greene FL, Gospodarowicz M, Wittekind C, et al. American Joint Committee on Cancer (AJCC) staging manual. ed 7. Philadelphia, PA: Springer; 2009.
- [19] Patard JJ, Leray E, Cindolo L, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. *J Urol* 2004;172:858–62.
- [20] Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumors. *J Pathol* 1997;183:131–3.
- [21] Fuhrman S, Lasky LC, Limas L. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol* 1982;6:655–63.
- [22] Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. *Cancer* 2004;100:1–5.
- [23] Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. *Eur Urol* 2007;51:1502–10.
- [24] Novick AC, Campbell SC, Belldegrun A, et al. Guideline for management of the clinical stage 1 renal mass (2009). American Urological Association Web site. http://www.auanet.org/content/guidelinesand-quality-care/clinical-guidelines/main_reports/renalmass09.pdf.